SPRB — Spruce Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Spruce Biosciences Announces Positive Type B Meetings With U.S. FDA For Ta-Ert For The Treatment Of Sanfilippo Syndrome Type B
Brief: Spruce Biosciences Secures Up To $50 Million In Growth Capital From Avenue Capital
Oppenheimer starts Spruce Biosciences with "outperform" rating on rare disease strength
Brief: Spruce Biosciences Appoints Keli Walbert To Board Of Directors
Spruce Biosciences Q3 net loss narrows
Brief: Spruce Biosciences Announces $50.0 Million Private Placement Financing
U.S. STOCKS ON THE MOVE-Gilead, energy companies, Abercrombie & Fitch
U.S. STOCKS ON THE MOVE-Figure Technology, Spruce Biosciences, Verizon
Brief: Spruce Biosciences Announces Reverse Stock Split
Brief: Spruce Biosciences Inc - Approves 55% Workforce Reduction - SEC Filing
Spruce Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Spruce Biosciences Announces New Corporate Strategy And Acquisition Of Tralesinidase Alfa
Spruce Biosciences Inc expected to post a loss of 21 cents a share - Earnings Preview
Spruce Biosciences Inc expected to post a loss of 21 cents a share - Earnings Preview
Spruce Biosciences Inc expected to post a loss of 21 cents a share - Earnings Preview
Spruce Biosciences Inc expected to post a loss of 21 cents a share - Earnings Preview
Spruce Biosciences Inc expected to post a loss of 21 cents a share - Earnings Preview
Spruce Biosciences Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Spruce Biosciences Announces Topline Results From Cahmelia-204 In Adult CAH And Cahptain-205 In Adult And Pediatric CAH